新的前沿:合并分子降解剂和抗体-药物结合方式,克服战略挑战
Yam B Poudel1, Ruchita R Thakore2, Eugene P Chekler1
1Bristol Myers Squibb, 700 Bay Road, Redwood City, California 94063, United States.
Journal of medicinal chemistry
|September 4, 2024
概括
分子-抗体结合物 (MAC) 是癌症治疗的一种新方法,利用分子代替传统的细胞毒剂. 本综述探讨了针对这些基于cereblon的降解剂的有针对性的交付方面的进展.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 药物运输 药物运输 药物运输
背景情况:
- 传统的抗体-药物联合体 (ADC) 在癌症治疗中利用细胞毒性有效载荷.
- 针对蛋白质分解的化体 (PROTAC) 降解抗体结合体 (DACs) 提供了一种通过向蛋白质降解的替代方案.
- 通过新的输送策略来解决PROTAC生物可用性的挑战.
研究的目的:
- 审查分子-抗体结合物 (MAC) 的最新进展.
- 讨论基于cereblon的分子降解剂的有针对性的输送.
- 突出MACs作为瘤学的新治疗方式的潜力.
主要方法:
- 对抗体-药物联合体和分子剂的当前文献的综述.
- 对专注于大脑结合分子降解剂的研究进行分析.
- 探索新型有效载荷的抗体介导输送系统.
主要成果:
- 引入分子-抗体结合物 (MACs) 作为一个独特的ADC类.
- 针对PROTAC有效载荷的基于抗体的输送的演示,克服生物可用性问题.
- 脑结合分子的出现作为新型ADC中的有效载荷.
结论:
- MACs在向癌症治疗中提供了一个有前途的新途径.
- 通过抗体提供基于cereblon的分子的有针对性的输送是一个快速发展的领域.
- 对MAC的进一步研究可能会导致下一代癌症治疗.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
10:35Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
Published on: February 5, 2021
3.4K
相关概念视频
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Hybridoma Technology
14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K
